祛湿中药治疗代谢性疾病的疗效与安全性:随机对照试验的系统评价与Meta分析
该研究检索六大数据库至2024年8月,纳入122项随机对照试验共11252名2型糖尿病、高血压、血脂异常或肥胖患者,评估祛湿中药的疗效与安全性。Meta分析显示,祛湿中药联合生活方式可改善空腹血糖、舒张压和体重指数,作为药物治疗辅助可显著降低空腹血糖、餐后2小时血糖及血压,但调脂作用有限且不确定。整体不良事件未见增加,但证据质量受异质性和缺乏盲法限制。
要点
- 祛湿中药联合生活方式可改善空腹血糖、舒张压和BMI,但对餐后2小时血糖和收缩压影响有限。
- 作为药物治疗辅助,祛湿中药可显著降低空腹血糖、餐后2小时血糖、收缩压和舒张压。
- 葛根芩连汤对糖尿病、半夏白术天麻汤对高血压显示出潜力,茯苓为多病种关键组分。
核心结论
- 祛湿中药可作为高血压和糖尿病等代谢性疾病补充治疗,但需高质量随机对照试验确认其在血脂异常中的作用及最佳减肥方剂。
研究设计与样本
- 系统评价与Meta分析,检索六大医学数据库至2024年8月,纳入122项随机对照试验共11252名2型糖尿病、高血压、血脂异常或肥胖患者。
- 采用Cochrane偏倚风险评估工具,使用Review Manager 5.3进行Meta分析和森林图绘制,依据GRADE系统评价证据质量。
主要发现
- 祛湿中药联合生活方式干预可改善空腹血糖、舒张压和体重指数,但对餐后2小时血糖和收缩压影响有限。
- 祛湿中药作为药物治疗辅助可显著增强空腹血糖、餐后2小时血糖、收缩压和舒张压的降低效果。
- 祛湿中药对血脂谱的影响 modest 且不确定,对肥胖整体有益但未识别出证据稳健的突出方剂。
- 与单纯药物治疗相比,祛湿中药未观察到额外不良事件。
- 葛根芩连汤对糖尿病、半夏白术天麻汤对高血压显示出潜力,茯苓为多病种关键组分。
关键数值与推荐
- 纳入122项随机对照试验,共11252名参与者,干预为口服针对湿邪的中药。
- 证据质量因异质性和缺乏盲法而受限,多数研究规模较小,个体方剂证据质量不理想。
临床怎么用
- 临床可考虑将祛湿中药作为高血压和糖尿病的补充治疗,尤其在与生活方式干预或药物治疗联合时。
- 葛根芩连汤可用于糖尿病辅助治疗,半夏白术天麻汤可用于高血压辅助治疗,茯苓可作为多病种组方的关键药物。
- 对血脂异常和肥胖的祛湿中药应用需谨慎,因证据有限且不确定,应优先选择证据较充分的方剂。
局限性
- 纳入研究存在异质性且缺乏盲法,证据质量受限。
- 多数研究规模较小,个体中药方剂的证据质量不理想。
- 对血脂异常和肥胖的疗效证据有限且不确定,需进一步高质量随机对照试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Observational studies indicate a high prevalence of dampness syndrome in metabolic diseases from the perspective of traditional Chinese medicine theory. This systematic review and meta-analysis aimed to assess the efficacy and safety of Chinese herbal medicine (CHM) for metabolic conditions via the therapeutic approach of eliminating dampness. MATERIALS AND METHODS: Six medical databases were searched up to August 2024 to identify randomised controlled trials (RCTs) involving individuals with type 2 diabetes mellitus (T2DM), hypertension, dyslipidaemia, or obesity, where the intervention included oral CHM targeting dampness. Risk of bias was assessed using the Cochrane Collaboration's tool. Meta-analyses and forest plots were generated using Review Manager 5.3. Evidence quality was evaluated per the Grading of Recommendations Assessment, Development and Evaluation (GRADE). RESULTS: Meta-analyses of 122 RCTs (n = 11,252 participants) showed that dampness-eliminating CHM, when combined with lifestyle interventions, improved fasting plasma glucose (FPG), diastolic blood pressure (DBP), and body mass index (BMI), but exerted limited impacts on 2-h postprandial glucose (2hPG) and systolic blood pressure (SBP). When used as an adjunct to pharmacotherapy, CHM significantly enhanced reductions in FPG, 2hPG, SBP, and DBP. The effects of CHM on lipid profiles were modest and uncertain. Although dampness-eliminating CHM as a whole conferred benefits for obesity, no outstanding formula with robust evidence was identified. Across all included RCTs, no additional adverse events were observed compared to pharmacotherapy alone. Promising CHM formulae included Gegen Qinlian Decoction for diabetes and Banxia Baizhu Tianma Decoction for hypertension. Poria, derived from the sclerotia of Poria cocos (Schw.) Wolf., emerged as a key component across multiple conditions. Overall, while the meta-analysis suggested promising findings for dampness-eliminating CHM in modulating metabolic conditions, the certainty of evidence was limited due to heterogeneity and lack of blinding. Specifically, the quality of evidence for individual CHM formulae was unsatisfactory, as most studies were of small scale. CONCLUSION: Dampness-eliminating CHM may serve as a complementary therapy for metabolic diseases such as hypertension and diabetes. Further high-quality RCTs are required to confirm its role in dyslipidaemia and identify the most effective CHM formulae for obesity.
引用
- Liang Y, Yu H, Ren J, et al. Efficacy and safety of Chinese herbal medicine for metabolic conditions: a systematic review and meta-analysis of randomised controlled trials. Front Pharmacol. 2026. PMID: 41552833. doi:10.3389/fphar.2025.1644950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。